Related Experiment Video
Updated: Jun 18, 2026

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
From complexity to approval in the European Union: Regulatory pathways and data challenges in the evaluation of
Gaёlle Andriantafika1, Heidi Janssen1, Ewa Balkowiec-Iskra2
1European Medicines Agency, Amsterdam, the Netherlands.
Abstract:
Generating comprehensive evidence for regulatory evaluation of non-oncology orphan medicines (NOOMS) at the marketing authorisation stage remains challenging. We assessed patterns observed across NOOMS applications between 2006 and 2024 comparing standard with non-standard regulatory pathways: conditional marketing authorisation and marketing authorisation under exceptional circumstances. We examined how uncertainties in quality of evidence, efficacy, safety and therapeutic context affect regulatory decisions based on additional benefit-risk considerations in the EU regulatory context. This work highlights how data maturity, uncertainty in results and biological plausibility - rather than unmet medical need alone - shape the choice of regulatory pathway. Early proactive engagement with regulators, innovative development strategies and enhanced collaboration among stakeholders are needed to address these challenges and accelerate patient access to NOOMS.
Related Concept Videos
Clinical Trials: Overview
Drug Regulation
Drug Control Governance: Regulatory Bodies and Their Impact
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Preclinical Development: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

